Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2016 to Q2 2023

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
SYRS on Nasdaq
Shares outstanding
27,995,500
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Invus Global Management, LLC 3.8% $776,595 1,063,829 Invus Public Equities, L.P. 31 Dec 2024

Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2023 Q2 0 $0 -$585 0
2023 Q1 219 $585 $0 $2.67 1
2022 Q4 219 $786 -$5,676,979 $3.59 1
2022 Q3 881,719 $5,679,000 -$38,817,526 $6.44 3
2022 Q2 35,466,990 $34,123,327 -$9,580,328 $0.96 57
2022 Q1 40,350,833 $47,998,739 -$16,168,123 $1.19 84
2021 Q4 51,088,934 $165,679,422 +$3,040,601 $3.26 81
2021 Q3 50,124,177 $223,065,186 -$4,666,902 $4.47 94
2021 Q2 47,940,360 $259,939,712 -$112,363,836 $5.45 96
2021 Q1 60,879,433 $453,764,087 +$49,748,071 $7.48 98
2020 Q4 52,819,403 $571,213,544 +$86,532,115 $10.85 97
2020 Q3 46,018,197 $405,811,308 +$11,501,142 $8.84 90
2020 Q2 39,975,459 $425,248,905 +$6,981,083 $10.66 77
2020 Q1 44,878,307 $265,481,374 +$15,180,997 $5.93 63
2019 Q4 42,159,417 $290,644,730 -$5,243,394 $6.91 70
2019 Q3 39,221,551 $406,209,216 +$48,985,268 $10.38 60
2019 Q2 34,755,948 $320,532,040 +$101,990,543 $9.26 65
2019 Q1 23,798,128 $217,515,058 +$16,275,819 $9.14 63
2018 Q4 22,214,575 $123,732,000 +$988,222 $5.57 65
2018 Q3 20,621,215 $245,604,026 +$2,474,832 $11.91 74
2018 Q2 20,427,086 $208,559,142 +$16,523,370 $10.21 72
2018 Q1 18,505,367 $240,197,598 +$38,689,090 $12.98 54
2017 Q4 15,876,446 $154,480,194 +$4,664,844 $9.73 67
2017 Q3 12,030,506 $177,148,772 +$16,402,387 $14.72 64
2017 Q2 15,591,778 $250,870,545 +$43,720,018 $16.09 45
2017 Q1 12,876,396 $205,118,593 +$2,455,871 $15.93 41
2016 Q4 12,922,246 $157,133,459 +$1,763,172 $12.16 40
2016 Q3 12,757,094 $176,293,302 +$3,959,957 $13.87 34
2016 Q2 3,027,285 $37,841,000 +$37,841,063 $12.50 1